BLEX 404 Oral Liquid

DRUG2 trials

Sponsors

BioLite, Inc.

Conditions

Myelodysplastic Syndrome (MDS)Triple Negative Breast Cancer

Phase 1

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Not yet recruitingNCT02802423

BioLite, Inc.Triple Negative Breast Cancer

Start: 2027-01-01End: 2028-08-28Target: 44Updated: 2026-04-13

Phase 2

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Not yet recruitingNCT02944955

BioLite, Inc.Myelodysplastic Syndrome (MDS)

Start: 2027-01-01End: 2028-12-31Target: 52Updated: 2026-04-13